Phaseline

Companies › Strand Therapeutics

Strand Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
STX-001
Self-replicating RNA encoding IL-12 delivered via lipid nanoparticle (LNP) for intratumora
IL12Phase 1Advanced Solid TumorMay 2027
STX-003
LNP-formulated self-replicating mRNA encoding human IL-12 with miRNA target sites for cont
IL12Phase 1Advanced Solid TumorJul 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06249048STX-001Phase 1Advanced Solid TumorOncologyMay 2027
NCT07751042STX-003Phase 1Advanced Solid TumorOncologyJul 2030

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

IL12 (2)

Companies with the same targets

Geneos Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Sonnet BioTherapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals Trogenix

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.